Oxford Nanopore Technologies plc Stock

Equities

ONT

GB00BP6S8Z30

Advanced Medical Equipment & Technology

Real-time Estimate Cboe Europe 06:45:32 2024-05-02 am EDT 5-day change 1st Jan Change
102 GBX +0.74% Intraday chart for Oxford Nanopore Technologies plc -1.07% -51.30%
Sales 2023 170M 212M Sales 2024 * 189M 237M Capitalization 873M 1.09B
Net income 2023 -155M -194M Net income 2024 * -149M -186M EV / Sales 2023 9.19 x
Net cash position 2023 228M 286M Net cash position 2024 * 313M 392M EV / Sales 2024 * 2.96 x
P/E ratio 2023
-11 x
P/E ratio 2024 *
-6 x
Employees 1,238
Yield 2023 *
-
Yield 2024 *
-
Free-Float 69.93%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.44%
1 week-0.66%
Current month-16.20%
1 month-13.27%
3 months-33.06%
6 months-50.62%
Current year-51.10%
More quotes
1 week
91.24
Extreme 91.243
106.20
1 month
91.24
Extreme 91.243
125.30
Current year
91.24
Extreme 91.243
212.59
1 year
91.24
Extreme 91.243
279.00
3 years
91.24
Extreme 91.243
736.00
5 years
91.24
Extreme 91.243
736.00
10 years
91.24
Extreme 91.243
736.00
More quotes
Managers TitleAgeSince
Founder - 04-12-31
Director of Finance/CFO 42 Jan. 21
Chief Investment Officer - 18-12-31
Members of the board TitleAgeSince
Director/Board Member 66 21-06-23
Director/Board Member 58 Dec. 18
Chairman 59 22-07-31
More insiders
Date Price Change Volume
24-05-02 101.4 +0.20% 189 505
24-05-01 101.2 +2.90% 1,081,569
24-04-30 98.35 -5.61% 16,576,370
24-04-29 104.2 +7.53% 970,804
24-04-26 96.9 +4.08% 1,191,178

Delayed Quote London S.E., May 02, 2024 at 05:22 am EDT

More quotes
Oxford Nanopore Technologies plc is engaged in the generation of molecular sensing technology based on nanopores. The Company has developed a deoxyribonucleic (DNA)/ ribonucleic acid (RNA) sequencing technology. The Company’s segments include Life Science Research Tools, which offers products and services for research use, and COVID Testing, which provides products for SAR-Cov-2 testing. Its sequencing technology offers real-time analysis, in fully scalable formats from pocket to population scale, that can analyze native DNA or RNA and sequence any length of fragment to achieve short to ultra-long read lengths. Its products include MinION, GridION, PromethION, Flongle and others. MinION is a real-time device for DNA and RNA sequencing. GridION is a benchtop device designed to run and analyze up to five MinION or Flongle Flow Cells. Flongle is an adapter for MinION or GridION that enables direct, real-time DNA sequencing, or cDNA sequencing on smaller, single-use flow cells.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
1.012 GBP
Average target price
2.02 GBP
Spread / Average Target
+99.60%
Consensus